Trichomoniasis: Genotype and Phenotype Correlations in African American Women

NCT ID: NCT00998530

Last Updated: 2019-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

231 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-09-30

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis to be tested in this trial is that the different epidemiologic (including racial differences) and phenotypic manifestations exhibited by Trichomonas clinical isolates during infection are correlated with their genotypic strain classification. Two specific aims are proposed to test that hypothesis. Specific aim 1. Assess the significance of genotypic or phenotypic differences in the Trichomonas strains among African American women by HIV status. Specific aim 2. Determine the significance of genotypic or phenotypic differences in the Trichomonas strains circulating among women from two different racial groups, African American women and Caucasian women. The overall goals of these specific aims are to identify racial differences in the genotypic and phenotypic characteristics of Trichomonas strains, and to develop the ability to identify and classify Trichomonas infections in order to prioritize treatment and epidemiologic follow-up of individuals infected with isolates associated with adverse clinical outcomes (HIV transmission or acquisition, pregnancy complications, virulence, or drug resistance).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite serious public health consequences, its widespread prevalence, rising drug resistance and treatment failures, little has been done to study the role of T. vaginalis genotype in transmission, virulence, occurrence of mixed infections, and the spread of drug resistance, primarily due to the lack of suitable assays for rapid strain typing. Previously utilized genotyping techniques for Trichomonas are inadequate due to problems with speed of analysis, sensitivity, and reproducibility between different labs. Multilocus sequence typing (MLST) combines speed, sensitivity, portability, accuracy, and reliability by determining nucleotide sequence polymorphisms (SNPs) present in small DNA fragments (300-400 nt) that are amplified by polymerase chain reaction (PCR) from a number (usually 6-7) of neutrally selected housekeeping genes. MLST assigns an allele fragment number (AFN) for each unique SNP or combination of SNPs present in a gene fragment and uses these to identify unique sequence types (STs) based on the AFN combinations in the collection of all the genes analyzed. MLST has been used extensively to study epidemiology, population structure, virulence and evolution in pathogenic bacteria but only for fungi among eukaryotes, due to the difficulty of interpreting MLST data in diploid organisms. However, T. vaginalis differs from other eukaryotes, possessing a stable haploid set of six chromosomes, and the investigators have developed an MLST genotyping system for T. vaginalis clinical isolates. The data (AFNs and STs) generated for each T. vaginalis strain by the MLST scheme we develop will be deposited in a freely accessible internet database. This MLST scheme will then be used to examine the relationships between strain genotypes and the clinical, epidemiologic, and physiologic manifestations of trichomoniasis.

Trichomoniasis is characterized by a wide spectrum of clinical presentation and disease sequelae. This clinical variability is accompanied by a high degree of genetic diversity in Trichomonas vaginalis clinical isolates as we originally demonstrated and others have confirmed. The investigators hypothesize that correlations between genotype and clinical presentation are true for trichomoniasis and that T. vaginalis isolates differ in their capacity for clinical disease, severity, drug resistance, and disease sequelae. In support, several studies (10-40 patients) show a statistically significant correlation between the genetic relatedness of T. vaginalis isolates, using a random amplified polymorphic DNA (RAPD) technique, with their clinical presentation. Correlations between disease severity in trichomoniasis and in vitro phenotypic properties such as cytoadherence, cytotoxicity and expression of cysteine proteinase 30 kilo-dalton (kDa) protein have also been reported. Significant differences in cytoadherence to cell monolayers, differential protein expression, phagocytosis of target cells, ability to exert cytotoxic damage on cultured cells, and pathogenicity and mortality in mice have been demonstrated in T. vaginalis clinical isolates, indicating the wide variation in virulence properties present in Trichomonas isolates. The investigators have also demonstrated up to four-fold differences in secreted cysteine protease activity between cultured T. vaginalis clinical isolates. The accumulated evidence strongly supports a correlation between individual T. vaginalis strains and their capacity for virulence.

For this specific study, at the initial enrollment/diagnosis visit the investigators will collect T. vaginalis isolates accompanied by a detailed clinical assessment, epidemiological information, and the results of in vitro testing of drug .resistance. This information will allow the investigators to determine if particular strains or groups of strains (as determined by MLST genotyping) are associated with asymptomatic infection, clinical severity, patient race, treatment failures, drug resistance, mixed infections or sexual history using univariate and multivariate analysis. This is significant because positive associations of particular strains or groups of strains with these factors, as the investigators expect to find, will necessitate changes in the way trichomoniasis is managed and treated with reference to the strains identified. The investigators will also independently test these variables for correlations with each other to identify variables or combinations of variables which may be associated with clinical manifestations of trichomoniasis.

The information the investigators gather will also permit a better understanding of trichomoniasis in many additional ways. The investigators will culture T. vaginalis at test of cure (TOC) follow-up visits to genotype and determine their drug resistance in order to distinguish potential treatment failures or conversion to drug resistance (same genotype as original visit) from re-infection by another contact (different genotype). This is particularly significant for HIV+ women as their Trichomonas vaginalis infections are more difficult to cure and T. vaginalis may persist, undetectable by culture, only to re-emerge up to six months later. Trichomonas vaginalis is detected at TOC visits at much higher rates (up to 36 %) in HIV+ women than in HIV- women (8%) with most of these infections ascribed to treatment failures. Recent reports describe persistent, undetected T. vaginalis infections cultured 3 and 6 months after an initial negative TOC result in women who report no intervening sexual contacts. This is significant as a correlation of strain genotype with persistent infection will identify HIV+ individuals needing multiple TOC visits, use of more sensitive diagnostic tests, and perhaps longer treatment courses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Trichomonas Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

African American HIV+

African American women with HIV and infected with Trichomonas

No interventions assigned to this group

Caucasian HIV-

Caucasian women who are HIV negative and infected with Trichomonas

No interventions assigned to this group

African American HIV-

African American women who are HIV negative and are infected with Trichomonas

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Trichomonas infection

Exclusion Criteria

* pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mississippi State Department of Health

OTHER_GOV

Sponsor Role collaborator

University of Mississippi Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John C Meade, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Mississippi Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Women's Specialty Clinic at Mirror Lake

Flowood, Mississippi, United States

Site Status

University Physicians Grants Ferry

Flowood, Mississippi, United States

Site Status

Crossroads Clinics

Jackson, Mississippi, United States

Site Status

University Physicians Jackson Medical Mall

Jackson, Mississippi, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-0138

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

GRoup A StrePtococcus
NCT01558804 RECRUITING
Azithromycin for Meningococcal Carriage
NCT06618534 RECRUITING PHASE2
Mol Epi GrAS in Nicaragua
NCT00170521 TERMINATED